Gritstone Oncology Enters Licensing Agreement with Memorial Sloan Kettering


SAN FRANCISCO, Jan.12, 2016 — Gritstone Oncology, a cancer immunotherapy company developing next-generation, personalized cancer therapeutics, announced that the company has entered into an exclusive, worldwide licensing agreement and collaboration with Memorial Sloan Kettering Cancer Center (MSK).

Under the terms of the agreement, Gritstone will receive exclusive rights to intellectual property, research data, bioinformatics tools, and know-how that will support the discovery and development of novel tumor-specific neo-antigen (TSNA) based immunotherapies.

Subscribe to get the latest news